Trans-translation is a novel antibacterial target


We have demonstrated that our lead compounds inhibit non-stop ribosome rescue,
acting as potent antimicrobials against a range of pathogens, including MRSA
(and all other major CAP pathogens), Neisseria gonorrhoeae (among several
STD pathogens), M. tuberculosis, and Francisella tularensis (among other biodefense
targets). These compounds exhibit minimal toxicity towards mammalian cells,
excellent pharmacokinetics, oral bioavailability, tolerability and antibiotic
activity in multiple in vivo models.